Medical device startup in Galway AuriGen Medical Launched a €750,000 crowdfunding campaign to help fund clinical trials of the innovative heart transplant.
NUI Galway, founded in 2017, has developed a cardiac implant designed to treat the risk of stroke and arrhythmias associated with atrial fibrillation. The minimally invasive implant aims to revolutionize the management of millions of chronic heart patients.
Co-founder and CEO of AuriGen Medical Dr. John Thompson She said current approaches to treating heart failure and atrial fibrillation require multiple expensive devices and procedures.
“Despite the great focus and progress in treating chronic heart disease, it still kills more Europeans than cancer,” he said.
“Atrial fibrillation is a jittery or irregular heartbeat (irregular heartbeat) that can lead to blood clots, stroke, and heart failure.”
He explained that the elevated stroke risk could be controlled by closing off the left atrial appendage, which is a small sac inside the heart. The left atrial appendage is the source of 90% of blood clots in atrial fibrillation, which leads to a higher risk of stroke.
Devices exist to filter out these blood clots, which reduces the risk of stroke. However, implanting these devices is challenging due to the sharp fixed spines used to hold the device in the heart, which can rupture the heart wall causing significant injury.
“The devices also provide no treatment for arrhythmias or heart failure, nor do they provide the ability to monitor patients at home after their procedure.”
To address these challenges, AuriGen Medical has created the first device to combine stroke prevention, heart failure monitoring, and arrhythmia management into a single 30-minute case procedure.
Patient data is transmitted directly from their mobile receiver to the cloud which the clinician can access immediately.
AuriGen aims to provide governments and private healthcare insurers with an alternative to the current expensive multi-procedure therapies currently required to treat patients with heart failure/arrhythmias.
The company recently raised €1.5m in taxpayer investment from the Western Development Commission and Enterprise Ireland.
CEO of Spark Crowdfunding Chris Berg He said AuriGen’s heart implant devices address the significant unmet medical need of patients with heart failure and atrial fibrillation.
“The minimum investment is only €100, and as an EIIS-eligible company, Irish investors are essentially getting a venture capital-quality investment at 40% off the price paid by professional investors,” Borg said.
Photo: AuriGen Co-Founder and CTO Tony O’Halloran with Leo Varadkar